Presentation (CTI)

OBJECTIVES: Uncontrolled vomiting is distressing for pediatrics and caregivers. Oral route of administration of antiemetic is a preferred convenient route. The readily acceptance of the medication was higher among the film group compared to the oral solution form. These oral dissolving films are promising in playing a crucial role in improving outcomes and adherence among pediatric patients. This analysis aims to measure the budget impact of ondansetron oral dissolving film vs oral solution in the chemotherapy induced nausea and vomiting (CINV) for pediatric patients over 5 days.
METHODS: A decision tree model was conducted to measure cost and consequences of ondansetron oral dissolving film vs oral solution in the CINV for pediatric patients who lack IV access from payer perspective. Direct medical costs were measured in EGPs based on financial year 2025. It includes drug acquisition costs based on the treatment dose and duration, health care staff costs and non-adherent patients’ costs. Unit cost data was captured from the Ministry of Health list, while the adherence rates was captured from literature. Sensitivity analysis was conducted to assure the results robustness.
RESULTS: The total costs of ondansetron oral dissolving film and oral solution were measured among 520 cases across Ministry of Health hospitals. The total direct medical costs of ondansetron oral dissolving film and oral solution are EGP 89,987 and EGP 172,612, respectively, generating total savings of EGP - 82,625 offering considerable cost savings of EGP 158 per patient per year.
CONCLUSIONS: Adoption of ondansetron oral dissolving film can generate budget savings, and improve patient outcomes and adherence from payer perspective in the CINV pediatric patients who lack IV access.